<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Antiplatelet drugs; Thrombosis: antiplatelet drugs; Cardiovascular disease: prevention: antiplatelet therapy; Aspirin: antiplatelet; Clopidogrel; Acute coronary syndrome; Dipyridamole; Prasugrel; Ticagrelor; Antiplatelet drugs: coronary stenting; Cardiovascular disease: coronary stenting, antiplatelet therapy; Glycoprotein IIb/IIIa inhibitors; Abciximab; Eptifibatide; Tirofiban" /><meta name="IX" content="Antiplatelet drugs; Thrombosis: antiplatelet drugs; Cardiovascular disease: prevention: antiplatelet therapy; Aspirin: antiplatelet; Clopidogrel; Acute coronary syndrome; Dipyridamole; Prasugrel; Ticagrelor; Antiplatelet drugs: coronary stenting; Cardiovascular disease: coronary stenting, antiplatelet therapy; Glycoprotein IIb/IIIa inhibitors; Abciximab; Eptifibatide; Tirofiban" /><title>2.9 Antiplatelet drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1519-antiplatelet-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1519-antiplatelet-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1519-antiplatelet-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1517-protamine-sulfate.htm" title="Previous: PROTAMINE SULFATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1524-management-of-stroke.htm" title="Next: Management of stroke">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>2.9 </span>Antiplatelet drugs</h1><?highlighter on?><div id="pC" class="jN"><p>Antiplatelet drugs decrease platelet aggregation and inhibit thrombus formation in the arterial circulation, because in faster-flowing vessels, thrombi are composed mainly of platelets with little fibrin.</p> <p>Use of <strong>aspirin</strong> in primary prevention of cardiovascular events, in patients with or without diabetes, is of unproven benefit. Long-term use of aspirin, in a dose of 75 mg daily, is of benefit in established cardiovascular disease (secondary prevention); unduly high blood pressure must be controlled before aspirin is given. If the patient is at a high risk of gastro-intestinal bleeding, a proton pump inhibitor (<a title="BNF:sub-section: Proton pump inhibitors" href="PHP431-proton-pump-inhibitors.htm">section 1.3.5</a>) can be added.</p> <p>Aspirin in a dose of 75–300 mg daily is given following coronary bypass surgery. For details on the use of aspirin in atrial fibrillation see <a title="BNF:target-block: Atrial fibrillation" href="PHP893-management-of-arrhythmias.htm#PHP894">section 2.3.1</a>; for intermittent claudication see section <a title="BNF:sub-section: Peripheral vasodilators and related drugs" href="PHP1393-peripheral-vasodilators-and-related-drugs.htm">2.6.4</a>; for stable angina and acute coronary syndromes see section <a title="BNF:sub-section: Management of stable angina and acute coronary syndromes" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">2.10.1</a>; for use following placement of coronary stents see <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="PHP1519-antiplatelet-drugs.htm#PHP1523">below</a>; for use in stroke see also <a title="BNF:topic: Management of stroke" href="PHP1524-management-of-stroke.htm">below</a>.</p> <p><strong>Clopidogrel</strong> is licensed for the prevention of atherothrombotic events in patients with a history of symptomatic ischaemic disease. Clopidogrel, in combination with low-dose aspirin, is also licensed for acute coronary syndrome without ST-segment elevation (<a title="BNF:topic: Management of unstable angina and non-ST-segment elevation myocardial infarction" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm">section 2.10.1</a>); in these circumstances the combination is given for up to 12 months (most benefit occurs during the first 3 months; there is no evidence of benefit beyond 12 months). Clopidogrel, in combination with low-dose aspirin, is also licensed for acute myocardial infarction with ST-segment elevation (<a title="sub-section: Management of myocardial infarction" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">section 2.10.1</a>); the combination is licensed for at least 4 weeks, but the optimum treatment duration has not been established. In patients undergoing percutaneous coronary intervention, clopidogrel is used as an adjunct with aspirin (see also below). Patients, who are not already taking clopidogrel, should receive a 300 mg loading dose prior to the procedure; alternatively, a 600 mg [unlicensed] loading dose may produce a greater and more rapid inhibition of platelet aggregation.</p> <p>Clopidogrel is also licensed, in combination with low-dose aspirin, for the prevention of atherothrombotic and thromboembolic events in patients with atrial fibrillation (and at least one risk factor for a vascular event), and for whom warfarin is unsuitable.</p> <p>Use of clopidogrel with aspirin increases the risk of bleeding. Clopidogrel monotherapy may be an alternative when aspirin is contra-indicated, for example in those with aspirin hypersensitivity, or when aspirin is not tolerated despite the addition of a proton pump inhibitor (see also NICE guidance, below).</p> <p>For details on the use of clopidogrel in stroke, see <a title="BNF:topic: Management of stroke" href="PHP1524-management-of-stroke.htm">below</a>.</p> <p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (February 2004) that clopidogrel be accepted for restricted use for the treatment of confirmed acute coronary syndrome (without ST-segment elevation), in combination with aspirin. Clopidogrel should be initiated in hospital inpatients <strong>only</strong>. The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has also advised (July 2007) that clopidogrel be accepted for restricted use for patients with ST-segment elevation acute myocardial infarction in combination with aspirin; treatment with clopidogrel is restricted to 4 weeks only.</p> <p><strong>Dipyridamole</strong> is used by mouth as an adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. Modified-release preparations are licensed for secondary prevention of ischaemic stroke and transient ischaemic attacks (see also Long-term Management, under Ischaemic Stroke, <a title="BNF:topic: Ischaemic stroke" href="PHP1526-ischaemic-stroke.htm">below</a>).</p> <div id="PHP1520" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (December 2010)</h3><p>The guidance applies to patients who have had an occlusive vascular event, or who have established peripheral arterial disease. The guidance does <strong>not</strong> apply to patients who have had, or are at risk of, stroke associated with atrial fibrillation, or who need prophylaxis for occlusive events following coronary revascularisation or carotid artery procedures.</p><p>Clopidogrel monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:</p><ul><li><p>an ischaemic stroke, or who have peripheral arterial disease or multivascular disease, <strong>or</strong></p> </li><li><p>a myocardial infarction, only if aspirin is contra-indicated or not tolerated.</p> </li></ul><p>Modified-release dipyridamole, in combination with aspirin, is recommended as an option to prevent occlusive vascular events in patients who have had:</p><ul><li><p>a transient ischaemic attack, <strong>or</strong></p> </li><li><p>an ischaemic stroke, only if clopidogrel is contra-indicated or not tolerated.</p> </li></ul><p>Modified-release dipyridamole monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:</p><ul><li><p>an ischaemic stroke, only if aspirin and clopidogrel are contra-indicated or not tolerated, <strong>or</strong></p> </li><li><p>a transient ischaemic attack, only if aspirin is contra-indicated or not tolerated.</p> </li></ul></div> <p><strong>Prasugrel</strong>, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (<a title="BNF:topic: Management of unstable angina and non-ST-segment elevation myocardial infarction" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm">section 2.10.1</a>); the combination is usually given for up to 12 months.</p> <p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (August 2009) that prasugrel (<em>Efient</em>®), in combination with aspirin, be accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention who are eligible to receive the 10 mg dose of prasugrel.</p> <div id="PHP1521" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (October 2009)</h3><p>Prasugrel, in combination with aspirin, is an option for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention, only when: </p><ul><li><p>immediate primary percutaneous coronary intervention is necessary for ST-segment elevation myocardial infarction, <strong>or</strong></p> </li><li><p>stent thrombosis occurred during treatment with clopidogrel, <strong>or</strong></p> </li><li><p>the patient has diabetes mellitus.</p> </li></ul></div> <p><strong>Ticagrelor</strong>, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome; the combination is usually given for up to 12 months.</p> <div id="PHP1522" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Ticagrelor for the treatment of acute coronary syndromes (October 2011)</h3><p>Ticagrelor, in combination with low-dose aspirin, is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes, that is, people:</p><ul><li><p>with ST-segment elevation myocardial infarction—defined as ST elevation or new left bundle branch block on electrocardiogram—that cardiologists intend to treat with primary percutaneous coronary intervention, <strong>or</strong></p> </li><li><p>with non-ST-segment elevation myocardial infarction (NSTEMI), <strong>or</strong></p> </li><li><p>admitted to hospital with unstable angina—defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the characteristics defined below. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist. Characteristics to be used in defining treatment with ticagrelor for unstable angina are:</p><ul><li><p>age 60 years or older;</p> </li><li><p>previous myocardial infarction or previous coronary artery bypass grafting;</p> </li><li><p>coronary artery disease with stenosis of 50% or more in at least two vessels;</p> </li><li><p>previous ischaemic stroke;</p> </li><li><p>previous transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation;</p> </li><li><p>diabetes mellitus;</p> </li><li><p>peripheral arterial disease, <strong>or</strong></p> </li><li><p>chronic renal dysfunction (creatinine clearance less than 60 mL/minute/1.73 m<sup>2</sup>).</p> </li></ul> </li></ul></div> <div id="PHP1523"><h2>Antiplatelet drugs and coronary stents</h2><p>Patients selected for percutaneous coronary intervention, with the placement of a coronary stent, will require dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel, or ticagrelor. Aspirin therapy should continue indefinitely. Clopidogrel is recommended for 1 month following elective percutaneous coronary intervention with placement of a bare-metal stent, and for 12 months if percutaneous coronary intervention with placement of a bare-metal stent was for an acute coronary syndrome; clopidogrel should be given for 12 months following placement of a drug-eluting stent. Clopidogrel should not be discontinued prematurely in patients with a drug-eluting stent—there is an increased risk of stent thrombosis as a result of the eluted drug slowing the re-endothelialisation process. Patients considered to be at high risk of developing late stent thrombosis with a drug-eluting stent may require a longer duration of treatment with clopidogrel. Prasugrel or ticagrelor are alternatives to clopidogrel in certain patients undergoing percutaneous coronary intervention (see notes above).</p></div> <div><h2>Glycoprotein IIb/IIIa inhibitors</h2><p> Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation by blocking the binding of fibrinogen to receptors on platelets. <strong>Abciximab</strong> is a monoclonal antibody which binds to glycoprotein IIb/IIIa receptors and to other related sites; it is licensed as an adjunct to unfractionated heparin and aspirin for the prevention of ischaemic complications in high-risk patients undergoing percutaneous transluminal coronary intervention. Abciximab should be used once only (to avoid additional risk of thrombocytopenia). <strong>Eptifibatide</strong> and <strong>tirofiban</strong> also inhibit glycoprotein IIb/IIIa receptors; they are licensed for use with unfractionated heparin and aspirin to prevent early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (<a title="BNF:sub-section: Management of myocardial infarction" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">section 2.10.1</a>). Abciximab, eptifibatide and tirofiban should be used by specialists only.</p><p>For use of epoprostenol, see <a title="monograph-family: Epoprostenol" href="PHP1478-epoprostenol.htm">section 2.8.1</a>.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="PHP1524-management-of-stroke.htm" title="Management of stroke">Management of stroke</a></li><li><a href="PHP1525-transient-ischaemic-attack.htm" title="Transient ischaemic attack">Transient ischaemic attack</a></li><li><a href="PHP1526-ischaemic-stroke.htm" title="Ischaemic stroke">Ischaemic stroke</a></li><li><a href="PHP1528-intracerebral-haemorrhage.htm" title="Intracerebral haemorrhage">Intracerebral haemorrhage</a></li><li id="_PHP1529-abciximab"><a href="PHP1529-abciximab.htm" title="ABCIXIMAB">ABCIXIMAB</a></li><li id="_PHP1531-aspirin-antiplatelet"><a href="PHP1531-aspirin-antiplatelet.htm" title="ASPIRIN (antiplatelet)">ASPIRIN (antiplatelet)</a></li><li id="_PHP1537-clopidogrel"><a href="PHP1537-clopidogrel.htm" title="CLOPIDOGREL">CLOPIDOGREL</a></li><li id="_PHP1541-dipyridamole"><a href="PHP1541-dipyridamole.htm" title="DIPYRIDAMOLE">DIPYRIDAMOLE</a></li><li id="_PHP1550-eptifibatide"><a href="PHP1550-eptifibatide.htm" title="EPTIFIBATIDE">EPTIFIBATIDE</a></li><li id="_PHP1552-prasugrel"><a href="PHP1552-prasugrel.htm" title="PRASUGREL">PRASUGREL</a></li><li id="_PHP1554-ticagrelor"><a href="PHP1554-ticagrelor.htm" title="TICAGRELOR">TICAGRELOR</a></li><li id="_PHP1557-tirofiban"><a href="PHP1557-tirofiban.htm" title="TIROFIBAN">TIROFIBAN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1517-protamine-sulfate.htm">Previous: PROTAMINE SULFATE</a> | <a class="top" href="PHP1519-antiplatelet-drugs.htm#">Top</a> | <a accesskey="]" href="PHP1524-management-of-stroke.htm">Next: Management of stroke</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>